Novo Nordisk A/S
Novo Nordisk is a battered franchise with elite margins, repeated EPS beats, and a depressed 9.82x P/E that already discounts a bad FY26, while oral and next-wave obesity products preserve meaningful earnings power beyond the current pricing reset.
Novo trades like a broken obesity story. The numbers say it is a bruised one, not a broken one. At $38.42, the market is paying 9.82x earnings for a company that still generated $47.3B of FY2025 revenue, $3.53 of EPS, and a 44.5% operating margin. That multiple would make sense for a structurally declining pharma asset with weak execution. Novo instead has a recent record of 8 straight EPS beats, a still-dominant obesity franchise, and a new oral GLP-1 format that already posted DKK 2.3B of Q1 sales.
The market is correctly focused on the real problem: pricing. FY26 guidance is ugly even after the raise, with adjusted sales growth and operating profit growth both at -4% to -12% CER. Q1 adjusted sales were down 4%, U.S. operations were down 11%, and gross margin fell 290 bps to 80.6%. Those are not cosmetic issues. They show Novo has moved from a scarcity-driven model to a negotiation-driven one, especially in the U.S. That is why conviction is low. The stock does not need a perfect recovery, but it does need evidence that price erosion moderates before investors will pay more than a distressed multiple.
The reason to own the shares anyway is that the setup is asymmetric after a 40.1% drawdown from the 52-week high and 16.5% below the 200-day average. Obesity care still grew 22%, international obesity grew 44%, and Wegovy holds about 65% of NBRx. Oral Wegovy has broad PBM access at parity with injection, which matters more than the launch optics alone. If Novo can turn oral demand into recurring sell-through, then FY26 is likely the trough year the valuation already assumes.
The case depends on three things. First, U.S. realized pricing has to stop getting worse. Second, oral Wegovy needs to convert beyond the $150M of pipeline fill in Q1. Third, the next wave, including CagriSema and other pipeline assets, must keep Novo's obesity moat relevant as competition broadens. If those hold, the current price is too low. If they break, the multiple is cheap for a reason.
Oral Wegovy scales cleanly, CagriSema timing holds, U.S. pricing stabilizes faster than feared, and the market rewards Novo with a still discounted but materially higher multiple.
FY26 marks the earnings trough, obesity volume offsets part of the price reset, and the stock rerates toward the engine target as confidence in 2027 recovery improves.
U.S. pricing keeps deteriorating, FY26 lands near the low end of -12%, oral Wegovy pipeline fill fades, and the market values Novo as an ex-growth pharma asset.
Quant call (BUY) diverges from analyst consensus (Strong Sell: 0 buy / 0 hold / 1 sell) — resolve explicitly.
The time to buy is when there's blood in the streets.
Forward earnings power is better than the headline FY26 decline implies, because the current 9.82x P/E prices Novo like a structurally impaired business rather than a company still defending obesity share at about 65% and scaling a new oral format. The moat is narrower than it was two years ago because pricing power is weaker and generics are emerging in Canada, but 3 to 5 years out Novo still has brand, reimbursement access, device know-how, manufacturing scale, and a deep incretin pipeline that many peers do not. AI is not a direct product catalyst here, but it should marginally help trial design, commercial targeting, and manufacturing planning rather than disrupt the franchise; regulation and payer behavior matter far more, especially U.S. obesity coverage and realized pricing. TAM is still large, but the market now needs evidence that Novo can translate volume growth into profit growth again.
- Valuation is compressed at 9.82x P/E and 3.46x P/S, versus peer averages of 29.5x and 4.3x.
- Core economics remain strong with FY2025 revenue $47.3B, EPS $3.53, and 44.5% operating margin.
- Execution has held up, with 8 straight quarterly EPS beats, including +17.1%, +19.5%, and +11.1% in the last three reports.
- Novo still produced 17.5% YoY revenue growth and 16.7% YoY EPS growth in FY2025, with operating margin improving to 44.5% from 44.2%.
- The obesity franchise is still growing underneath the pricing noise: obesity care was up 22%, international obesity sales up 44%, and Wegovy leads new-to-brand prescriptions with about 65% share.
- Oral Wegovy is off to a fast start with DKK 2.3B Q1 sales, more than 2M prescriptions since launch, and more than 1M people treated, while broad PBM access was secured at parity with injection.
- Management is executing on cost control, with a transformation program targeting DKK 8B savings and headcount down almost 10,000 YoY, which should cushion the gross margin pressure from lower realized prices.
- FY26 guidance is still negative even after the raise: adjusted sales growth -4% to -12% CER and adjusted operating profit growth -4% to -12% CER.
- U.S. operations were down 11% on an adjusted basis, and Q1 adjusted sales fell 4% despite strong GLP-1 volume because pricing deteriorated.
- Gross margin compressed to 80.6% from 83.5%, a 290 bps drop, on lower realized prices, one-time costs, and FX.
- The oral Wegovy launch is strong but not clean, because $150M of Q1 sales came from pipeline fill and management said supply is not unlimited, which raises the risk of uneven near-term demand translation.
| Metric | Value | Context |
|---|---|---|
| Share price | $38.42 | Current reference price |
| Quant price target | $66.97 | Ground-truth target, 74.3% above current, low confidence |
| FY2025 revenue | $47.3B | 17.5% YoY growth |
| FY2025 EPS | $3.53 | 16.7% YoY growth |
| Operating margin | 44.5% | Up from 44.2% prior FY |
| Net margin | 34.5% | Still elite for large-cap pharma |
| Valuation | P/E 9.82, P/S 3.46, P/B 5.15 | Below peer averages of 29.5x P/E and 4.3x P/S |
| Balance sheet | Debt/Equity 0.63, Debt/EBITDA 0.89 | Leverage is manageable |
| Free cash flow | $6.5B | Supports capex and modest buybacks |
| FY26 guidance | Sales -4% to -12% CER, OP -4% to -12% CER | Raised by 1 ppt, but still negative |
| Earnings track record | 8 straight beats | Latest three beats were +11.1%, +19.5%, and +17.1% |
| 52-week position | Range $35.12-$64.16 | Stock is -40.1% from high and -16.5% below 200-day average |
The biggest risk is that U.S. price erosion persists long enough to turn FY26's guided -4% to -12% sales and operating profit decline into a multi-year earnings reset rather than a one-year trough.
The next catalyst is November 4, 2026 earnings, where investors need proof that oral Wegovy demand is converting into real sell-through and that FY26 guidance can stabilize despite U.S. pricing pressure.
Positioning is not crowded. Short interest is only 1.00% of shares, or 31.6M shares, with 2.6 days-to-cover, and it fell 6.4%, so this is not set up as a squeeze. Options positioning is more fragile, with a negative gamma regime and zero-gamma at $41.29, above spot by 7.48%, which can amplify downside until the stock reclaims that zone; ownership is also diffuse, with the top three institutions holding only 6.7% combined.
Most important swing factor near term, with U.S. operations -11% on an adjusted basis in Q1 because realized pricing fell.
Still a major growth engine, with international obesity sales +44%.
Obesity care grew 22%, supported by Wegovy, including the new oral launch.
Launch is very strong, but $150M of Q1 sales reflected pipeline fill and supply is constrained.
Novo raised FY26 guidance by 1 ppt, helped by stronger GLP-1 expectations and rapid Wegovy pill uptake.
Management's credibility is mixed but still net positive. On the positive side, the company delivered 8 straight quarterly EPS beats, including +32.5% in 2025-11 and +19.5% in 2026-05, and FY2025 still posted 17.5% revenue growth with operating margin improving to 44.5%. Against the 2024 Q2 call, management had guided FY24 net sales growth of 22%-28% CER, operating profit growth of 20%-28% CER, capex around DKK45B, and free cash flow of DKK59B-DKK69B, while stressing supply expansion and the Catalent close toward end-2024. Since then, strategy has clearly shifted from pure volume expansion to defending profitability through pricing pressure, cost saves, and portfolio mix, because FY26 now guides to -4% to -12% sales and operating profit growth at CER. They did execute on launch cadence, with oral Wegovy at DKK 2.3B Q1 sales and more than 2M prescriptions, but they have not preserved the old pricing power, shown by gross margin falling from 83.5% to 80.6% and U.S. adjusted operations declining 11%.
For 2026, adjusted sales growth is now expected to be between minus 4% and minus 12% at CER. The improvement in outlook is mainly driven by increased expectations for GLP-1 product sales.
Adjusted operating profit growth is now expected to be minus 4% to minus 12% at CER.
In the first 3 months of 2026, our reported sales increased by 32%, reaching DKK 96.8 billion. That means our adjusted sales declined by 4%, driven by lower realized prices, partly offset by GLP-1 volume growth and market expansion.
Based on that, we're more confident in our outlook, and as a consequence, we parallel shifted both sales and OP ranges by 1 percentage point. You should take it as a signal of confidence that we lifted the range by 1 percentage point.
While we do not have unlimited supply for the Wegovy pill due to product design, despite setting a new record for product uptake in the U.S., we are still able to announce launches in the first markets ex U.S. already this year.
Novo's moat comes from a rare combination of metabolic disease expertise, brand trust with prescribers, payer access, and manufacturing scale in GLP-1s. That moat is still real, but less absolute than in 2024 because lower realized prices and emerging generic pressure in Canada show that economics can be competed away faster than volumes. Durability over the next 3 to 5 years depends on keeping leadership in obesity outcomes and formulation innovation, especially oral and next-generation combinations, not just defending today's injectables.
Capital allocation looks functional, not shareholder-friendly. FY2025 free cash flow was $6.5B, capex was $2.0B, and buybacks were only $0.5B, with $0.0B dividends in the provided data, which is light for a company of this quality trading at 9.82x earnings. The positive read is that Novo has kept investing in capacity and is also driving efficiency through a transformation program targeting DKK 8B savings.
Novo rates BUY, Low conviction. The stock already reflects a lot of bad news, with a 9.82x P/E and a 40.1% drop from the 52-week high, while the business still throws off elite margins and continues to beat earnings expectations. This is not a clean turnaround call, because FY26 guidance is still negative and U.S. pricing remains the issue that matters. The buy case works if November results show oral Wegovy demand is real beyond inventory fill and that pricing pressure is stabilizing. A downgrade would require evidence that the FY26 decline is not a trough but the start of a lasting earnings impairment.
≣ Full research note tap to expand
Executive Summary
BUY, Low conviction. Rated BUY, Low conviction. The stock is down 40.1% from its 52-week high and trades at 9.82x earnings despite 44.5% operating margin, 17.5% FY2025 revenue growth, and eight straight quarterly EPS beats. The catch is real: FY26 guidance still calls for declining sales and operating profit, U.S. pricing is weak, and confidence should stay low until November results prove the GLP-1 franchise can absorb the pricing reset.
Investment Thesis
Novo trades like a broken obesity story. The numbers say it is a bruised one, not a broken one. At $38.42, the market is paying 9.82x earnings for a company that still generated $47.3B of FY2025 revenue, $3.53 of EPS, and a 44.5% operating margin. That multiple would make sense for a structurally declining pharma asset with weak execution. Novo instead has a recent record of 8 straight EPS beats, a still-dominant obesity franchise, and a new oral GLP-1 format that already posted DKK 2.3B of Q1 sales.
The market is correctly focused on the real problem: pricing. FY26 guidance is ugly even after the raise, with adjusted sales growth and operating profit growth both at -4% to -12% CER. Q1 adjusted sales were down 4%, U.S. operations were down 11%, and gross margin fell 290 bps to 80.6%. Those are not cosmetic issues. They show Novo has moved from a scarcity-driven model to a negotiation-driven one, especially in the U.S. That is why conviction is low. The stock does not need a perfect recovery, but it does need evidence that price erosion moderates before investors will pay more than a distressed multiple.
The reason to own the shares anyway is that the setup is asymmetric after a 40.1% drawdown from the 52-week high and 16.5% below the 200-day average. Obesity care still grew 22%, international obesity grew 44%, and Wegovy holds about 65% of NBRx. Oral Wegovy has broad PBM access at parity with injection, which matters more than the launch optics alone. If Novo can turn oral demand into recurring sell-through, then FY26 is likely the trough year the valuation already assumes.
The case depends on three things. First, U.S. realized pricing has to stop getting worse. Second, oral Wegovy needs to convert beyond the $150M of pipeline fill in Q1. Third, the next wave, including CagriSema and other pipeline assets, must keep Novo's obesity moat relevant as competition broadens. If those hold, the current price is too low. If they break, the multiple is cheap for a reason.
Key Metrics
| Metric | Value | Context |
|---|---|---|
| Share price | $38.42 | Current reference price |
| Quant price target | $66.97 | Ground-truth target, 74.3% above current, low confidence |
| FY2025 revenue | $47.3B | 17.5% YoY growth |
| FY2025 EPS | $3.53 | 16.7% YoY growth |
| Operating margin | 44.5% | Up from 44.2% prior FY |
| Net margin | 34.5% | Still elite for large-cap pharma |
| Valuation | P/E 9.82, P/S 3.46, P/B 5.15 | Below peer averages of 29.5x P/E and 4.3x P/S |
| Balance sheet | Debt/Equity 0.63, Debt/EBITDA 0.89 | Leverage is manageable |
| Free cash flow | $6.5B | Supports capex and modest buybacks |
| FY26 guidance | Sales -4% to -12% CER, OP -4% to -12% CER | Raised by 1 ppt, but still negative |
| Earnings track record | 8 straight beats | Latest three beats were +11.1%, +19.5%, and +17.1% |
| 52-week position | Range $35.12-$64.16 | Stock is -40.1% from high and -16.5% below 200-day average |
Financial Strength
Financial quality remains the main reason not to get bearish at this level. A 44.5% operating margin, 34.5% net margin, and 0.89x debt/EBITDA are strong enough to absorb a year of negative operating growth without balance-sheet stress. The weak point is liquidity optics, with a 0.87 current ratio and only mid-tier cash flow quality in the scorecard, but the bigger issue is not solvency, it is conversion of volume growth into cash earnings after pricing pressure. As long as margins stabilize above current levels and free cash flow stays positive, the balance sheet gives Novo time to work through the reset.
Competitive Position
Novo's moat comes from a rare combination of metabolic disease expertise, brand trust with prescribers, payer access, and manufacturing scale in GLP-1s. That moat is still real, but less absolute than in 2024 because lower realized prices and emerging generic pressure in Canada show that economics can be competed away faster than volumes. Durability over the next 3 to 5 years depends on keeping leadership in obesity outcomes and formulation innovation, especially oral and next-generation combinations, not just defending today's injectables.
Management & Guidance
Management is guiding conservatively but not capitulating. The exact FY26 guide is adjusted sales growth of -4% to -12% CER and adjusted operating profit growth of -4% to -12% CER, both improved by 1 percentage point, with the CFO stating, "For 2026, adjusted sales growth is now expected to be between minus 4% and minus 12% at CER. The improvement in outlook is mainly driven by increased expectations for GLP-1 product sales." Credibility is helped by the streak of EPS beats and the clear operational detail around oral Wegovy uptake, cost savings, Awiqli H2 2026 launch timing, etavopivat submission in Q4 2026, and potential CagriSema U.S. launch around end-2026 or 2027. The reason not to assign high confidence is that the guide still embeds decline, and recent results show pricing pressure has been stronger than volume growth.
Segment Analysis
- Geography, U.S. (N/A): Most important swing factor near term, with U.S. operations -11% on an adjusted basis in Q1 because realized pricing fell.
- Geography, International obesity (N/A): Still a major growth engine, with international obesity sales +44%.
- Therapy area, Obesity care (N/A): Obesity care grew 22%, supported by Wegovy, including the new oral launch.
- Product, Oral Wegovy (DKK 2.3B in Q1): Launch is very strong, but $150M of Q1 sales reflected pipeline fill and supply is constrained.
Capital Allocation
Capital allocation looks functional, not shareholder-friendly. FY2025 free cash flow was $6.5B, capex was $2.0B, and buybacks were only $0.5B, with $0.0B dividends in the provided data, which is light for a company of this quality trading at 9.82x earnings. The positive read is that Novo has kept investing in capacity and is also driving efficiency through a transformation program targeting DKK 8B savings.
Management Execution & Track Record
Management's credibility is mixed but still net positive. On the positive side, the company delivered 8 straight quarterly EPS beats, including +32.5% in 2025-11 and +19.5% in 2026-05, and FY2025 still posted 17.5% revenue growth with operating margin improving to 44.5%. Against the 2024 Q2 call, management had guided FY24 net sales growth of 22%-28% CER, operating profit growth of 20%-28% CER, capex around DKK45B, and free cash flow of DKK59B-DKK69B, while stressing supply expansion and the Catalent close toward end-2024. Since then, strategy has clearly shifted from pure volume expansion to defending profitability through pricing pressure, cost saves, and portfolio mix, because FY26 now guides to -4% to -12% sales and operating profit growth at CER. They did execute on launch cadence, with oral Wegovy at DKK 2.3B Q1 sales and more than 2M prescriptions, but they have not preserved the old pricing power, shown by gross margin falling from 83.5% to 80.6% and U.S. adjusted operations declining 11%.
Positioning & Flows
Positioning is not crowded. Short interest is only 1.00% of shares, or 31.6M shares, with 2.6 days-to-cover, and it fell 6.4%, so this is not set up as a squeeze. Options positioning is more fragile, with a negative gamma regime and zero-gamma at $41.29, above spot by 7.48%, which can amplify downside until the stock reclaims that zone; ownership is also diffuse, with the top three institutions holding only 6.7% combined.
Bull Case
- Novo still produced 17.5% YoY revenue growth and 16.7% YoY EPS growth in FY2025, with operating margin improving to 44.5% from 44.2%.
- The obesity franchise is still growing underneath the pricing noise: obesity care was up 22%, international obesity sales up 44%, and Wegovy leads new-to-brand prescriptions with about 65% share.
- Oral Wegovy is off to a fast start with DKK 2.3B Q1 sales, more than 2M prescriptions since launch, and more than 1M people treated, while broad PBM access was secured at parity with injection.
- Management is executing on cost control, with a transformation program targeting DKK 8B savings and headcount down almost 10,000 YoY, which should cushion the gross margin pressure from lower realized prices.
Bear Case
- FY26 guidance is still negative even after the raise: adjusted sales growth -4% to -12% CER and adjusted operating profit growth -4% to -12% CER.
- U.S. operations were down 11% on an adjusted basis, and Q1 adjusted sales fell 4% despite strong GLP-1 volume because pricing deteriorated.
- Gross margin compressed to 80.6% from 83.5%, a 290 bps drop, on lower realized prices, one-time costs, and FX.
- The oral Wegovy launch is strong but not clean, because $150M of Q1 sales came from pipeline fill and management said supply is not unlimited, which raises the risk of uneven near-term demand translation.
Valuation & Price Target
Engine price target $66.97 (+74.3% vs current), Low confidence.
- P/E Multiple: $779.98 (1% weight)
- PEG (growth-adjusted): $688.54 (0% weight)
- P/S Multiple: $50.02 (20% weight)
- Quality-adjusted: $44.81 (20% weight)
- DCF: $79.23 (4% weight)
The rating stays aligned with the quant baseline BUY, but with Low conviction rather than a stronger call. The engine's $66.97 target implies 74.3% upside, yet the valuation stack itself shows why confidence must stay restrained: P/E and PEG outputs of $779.98 and $688.54 are clearly distorted by unusually low current earnings multiples and are not useful anchors, while the more grounded methods cluster much lower at $50.02, $44.81, and $79.23. The average peer P/E of 29.5 comes with wide peer dispersion of 4.9x, so peer rerating alone is too fragile a thesis. The case for BUY rests instead on company specifics: 9.82x P/E, 44.5% operating margin, 0.89x debt/EBITDA, and repeated earnings beats against a stock already down 40.1% from the high. The lone sell-side view is low-signal context only and does not outweigh the operating data.
Risk Assessment
Risk score 41/100 (Moderate). The biggest risk is that U.S. price erosion persists long enough to turn FY26's guided -4% to -12% sales and operating profit decline into a multi-year earnings reset rather than a one-year trough.
The Bottom Line
Novo rates BUY, Low conviction. The stock already reflects a lot of bad news, with a 9.82x P/E and a 40.1% drop from the 52-week high, while the business still throws off elite margins and continues to beat earnings expectations. This is not a clean turnaround call, because FY26 guidance is still negative and U.S. pricing remains the issue that matters. The buy case works if November results show oral Wegovy demand is real beyond inventory fill and that pricing pressure is stabilizing. A downgrade would require evidence that the FY26 decline is not a trough but the start of a lasting earnings impairment.
Go deeper in the app
Live charts, options analytics, the full earnings-call breakdown, price alerts, and every other stock — updated in real time.
Get Tickr